Vedolizumab as induction and maintenance therapy for ulcerative colitis.

@article{Feagan2013VedolizumabAI,
  title={Vedolizumab as induction and maintenance therapy for ulcerative colitis.},
  author={Brian G. Feagan and Paul J. Rutgeerts and Bruce E. Sands and Stephen Hanauer and J F Colombel and William J Sandborn and Gert Van Assche and Jeffrey L. Axler and Hyo-Jong Kim and Silvio Danese and Irving H. Fox and Catherine E. Milch and Serap Sankoh and Tim Wyant and Jing Xu and Asit Parikh},
  journal={The New England journal of medicine},
  year={2013},
  volume={369 8},
  pages={
          699-710
        }
}
BACKGROUND Gut-selective blockade of lymphocyte trafficking by vedolizumab may constitute effective treatment for ulcerative colitis. METHODS We conducted two integrated randomized, double-blind, placebo-controlled trials of vedolizumab in patients with active disease. In the trial of induction therapy, 374 patients (cohort 1) received vedolizumab (at a dose of 300 mg) or placebo intravenously at weeks 0 and 2, and 521 patients (cohort 2) received open-label vedolizumab at weeks 0 and 2, with… Expand
Vedolizumab as induction and maintenance therapy for Crohn's disease.
TLDR
Vedolizumab-treated patients with active Crohn's disease were more likely than patients receiving placebo to have a remission, but not a CDAI-100 response, at week 6; patients with a response to induction therapy who continued to receive vedolIZumab (rather than switching to placebo) were morelikely to be in remission at week 52. Expand
Vedolizumab, a gut-specific monoclonal antibody, renews hope for an alternative to anti-TNF therapy in inflammatory bowel diseases
  • A. Rezaie
  • Medicine
  • Annals of gastroenterology
  • 2014
Recently, GEMINI 1 investigators examined the efficacy of vedolizumab for induction and maintenance of remission in active ulcerative colitis (Mayo score of 6-12 and unsuccessful previous treatmentExpand
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
TLDR
Vedolizumab was superior to adalimumab with respect to achievement of clinical remission and endoscopic improvement, but not corticosteroid-free clinical remission in adults with moderately to severely active ulcerative colitis. Expand
Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis.
TLDR
Subcutaneous vedolizumab is effective as maintenance therapy in patients with moderately to severely active UC who had a clinical response to intravenous vedolsumab induction therapy and has a favorable safety and tolerability profile. Expand
Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
TLDR
Vedolizumab was not more effective than placebo in inducing clinical remission at week 6 among patients with CD in whom previous treatment with TNF antagonists had failed, and the therapeutic benefits of vedolIZumab in these patients were detectable at week 10. Expand
Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease.
  • A. Amiot, J. Grimaud, +23 authors Y. Bouhnik
  • Medicine
  • Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2016
TLDR
In a cohort of patients with Crohn's disease or UC who failed previous anti-tumor necrosis factor therapy, approximately one third of patients achieved steroid-free clinical remission after 14 weeks of induction therapy with vedolizumab. Expand
Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis.
TLDR
The results indicate that the efficacy of vedolizumab SC in a subgroup of Japanese patients with UC are similar with those in the overall VISIBLE 1 study population, and with those established with vedOLizumAB IV. Expand
Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists
  • B. Feagan, D. Rubin, +5 authors M. Smyth
  • Medicine
  • Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2017
TLDR
Vedolizumab demonstrated significantly greater efficacy as induction and maintenance therapy for UC than placebo in patients naive to TNF antagonists and patients with TNF antagonist failure, for most outcomes. Expand
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
TLDR
In patients with moderately to severely active ulcerative colitis, tofacitinib was more effective as induction and maintenance therapy than placebo and was associated with increased lipid levels. Expand
Efficacy and Safety of Continued Treatment with Mirikizumab in a Phase 2 Trial of Patients with Ulcerative Colitis.
  • W. Sandborn, M. Ferrante, +11 authors B. Feagan
  • Medicine
  • Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2020
TLDR
Extended doses of mirikizumab (600 mg and 1000 mg) for an additional 12 weeks produce aclinical response in up to 50% of patients who did not have a clinical response to 12 weeks of induction doses, most of the responders to the extended doses maintained clinical response for up to 52 weeks. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 52 REFERENCES
Vedolizumab as induction and maintenance therapy for Crohn's disease.
TLDR
Vedolizumab-treated patients with active Crohn's disease were more likely than patients receiving placebo to have a remission, but not a CDAI-100 response, at week 6; patients with a response to induction therapy who continued to receive vedolIZumab (rather than switching to placebo) were morelikely to be in remission at week 52. Expand
Natalizumab induction and maintenance therapy for Crohn's disease.
TLDR
Induction therapy with natalizumab for Crohn's disease resulted in small, nonsignificant improvements in response and remission rates, which will need to be weighed against the risk of serious adverse events. Expand
Infliximab for induction and maintenance therapy for ulcerative colitis.
TLDR
Patients with moderate-to-severe active ulcerative colitis treated with infliximab at weeks 0, 2, and 6 and every eight weeks thereafter were more likely to have a clinical response at weeks 8, 30, and 54 than were those receiving placebo. Expand
Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.
TLDR
In this short-term study, MLN02 was more effective than placebo for the induction of clinical and endoscopic remission in patients with active ulcerative colitis. Expand
Oral 5-aminosalicylic acid for inducing remission in ulcerative colitis.
TLDR
The newer 5-ASA preparations were superior to placebo and tended towards therapeutic benefit over SASP, however, considering their relative costs, a clinical advantage to using the newer 4-aminosalicylic acid preparations in place of SASP appears unlikely. Expand
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
TLDR
It is concluded that oral 5-ASA administered in a dosage of 4.8 g per day is effective therapy, at least in the short term, for mildly to moderately active ulcerative colitis. Expand
Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
TLDR
Positive status with respect to anti-JC virus antibodies, prior use of immunosuppressants, and increased duration of natalizumab treatment, alone or in combination, were associated with distinct levels of PML risk in natalIZumab-treated patients with multiple sclerosis. Expand
Efficacy of Oral vs. Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Meta-Analysis
TLDR
Combined 5- ASA therapy appeared superior to oral 5-ASAs for induction of remission of mildly to moderately active UC and intermittent topical 5-asAs appeared superior for preventing relapse of quiescent UC. Expand
Fatal PML associated with efalizumab therapy
TLDR
It is proposed that inhibition of peripheral and intrathecal T-cell activation and suppression of CNS effector-phase migration both characterize efalizumab-associated PML and LFA-1 may be a crucial factor in homeostatic JC virus control. Expand
...
1
2
3
4
5
...